Glaukos Patent-Cliff Exposure & CMS Drug Spending Portfolio

Glaukos (US): 3 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2028-01-01
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 Filings4 WAC filings (max 45.7% 2-yr change)